تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | $3.2B | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.7B | $1.6B | $1.5B | $1.3B | $1.1B | $916M | $743M | $604M | $370M | $281M | $211M | $160M |
| إجمالي الربح | $2.7B | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B | $1.4B | $1.3B | $1.4B | $1.6B | $1.5B | $1.4B | $1.2B | $986M | $797M | $654M | $530M | $325M | $251M | $189M | $143M |
| هامش الربح الإجمالي % | 86.2% | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% | 92.7% | 91.9% | 87.8% | 93.9% | 95.5% | 95.3% | 90.2% | 88.3% | 87.0% | 88.0% | 87.8% | 87.8% | 89.3% | 89.5% | 89.3% |
| الدخل التشغيلي (EBIT) | $1.4B | $1.5B | $1.4B | $1.2B | $980M | $556M | $594M | ($188M) | $805M | $815M | $1.1B | $699M | $539M | $292M | $422M | $318M | $164M | $26M | ($82M) | $6M | $29M |
| هامش التشغيل % | 44.5% | 47.7% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | -13.0% | 49.5% | 47.2% | 66.4% | 47.7% | 41.8% | 26.2% | 46.0% | 42.8% | 27.2% | 7.0% | -29.1% | 3.0% | 18.2% |
| صافي الدخل | $1.3B | $1.3B | $1.2B | $985M | $727M | $476M | $515M | ($104M) | $589M | $418M | $714M | $652M | $340M | $175M | $304M | $218M | $106M | $19M | ($43M) | $20M | $74M |
| هامش الربح الصافي % | 41.5% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | -7.2% | 36.2% | 24.2% | 44.6% | 44.5% | 26.4% | 15.6% | 33.2% | 29.3% | 17.5% | 5.3% | -15.2% | 9.4% | 46.3% |
| EBITDA | — | $1.8B | $1.7B | $1.4B | $1.0B | $737M | $646M | ($75M) | $838M | $1.1B | $1.1B | $1.1B | $575M | $324M | $484M | $341M | $185M | $43M | ($68M) | $22M | $29M |
| ربحية السهم (EPS) | $27.86 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | $-2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 | $-0.93 | $0.44 | $1.53 |
| الأسهم القائمة (م) | — | 48M | 48M | 50M | 48M | 47M | 45M | 44M | 44M | 45M | 47M | 51M | 54M | 53M | 53M | 59M | 60M | 56M | 46M | 45M | 48M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ UTHR. /companies/us/UTHR
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms